<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115581</url>
  </required_header>
  <id_info>
    <org_study_id>CoenzymeQ10 and Cardiomyopathy</org_study_id>
    <nct_id>NCT02115581</nct_id>
  </id_info>
  <brief_title>Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy</brief_title>
  <official_title>Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tehran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tehran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the effect of Coenzyme Q10 supplementation on conventional
      therapy of children with heart failure due to idiopathic dilated cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine the effect of Coenzyme Q10 supplementation on conventional
      therapy of children with heart failure due to idiopathic dilated cardiomyopathy. In a
      prospective, randomized, double-blinded, placebo-controlled trial, patients younger than 18
      years with idiopathic dilated cardiomyopathy randomizes to receive either Coenzyme Q10 or
      placebo. Echocardiographic systolic and diastolic function parameters are determined for
      every patient at baseline, after three,six and nine months of supplementation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Left Ventricular Ejection Fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Ejection Fraction of left ventricle (percentage of blood pumped out of left ventricle with each heart beat) calculated by echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Left Ventricular Filling Abnormality</measure>
    <time_frame>6 months</time_frame>
    <description>Doppler-derived transmitral blood flow and pulmonary venous blood flow data were used for grading of the severity of diastolic filling abnormality in patients before and after the intervention. Diastolic filling abnormality was categorized as: 1- normal 2- abnormal relaxation 3- pseudonormal 4- restricted pattern based on echo data. The proportion of patients who showed improvement in the diastolic function grading was compared between the study groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with evidence of adverse reaction to coenzyme Q10 including nausea, vomiting, changes in blood pressure, neurological signs or any abnormal behavior like disquiet in young children.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Coenzyme Q10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.
Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>known cases of idiopathic dilated cardiomyopathy who received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance</description>
    <arm_group_label>Coenzyme Q10</arm_group_label>
    <other_name>Ubiquinone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>no brand name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known cases of Idiopathic Dilated Cardiomyopathy (IDC)

          -  Those patients in whom heart failure medications were stable for at least 1 month

          -  More than 6 months aged

        Exclusion Criteria:

          -  Recent modification in medications

          -  Hemodynamic instability

          -  Congenital heart disease

          -  Metabolic heart disease

          -  Cardiac dysfunction resulting from abnormalities in other organs and those with an
             acquired cardiomyopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Shabanian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Children's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armen Kocharian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giv Heidari-Bateni, MD/MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Tehran</city>
        <zip>14194</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <results_first_submitted>December 22, 2008</results_first_submitted>
  <results_first_submitted_qc>March 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2014</results_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tehran</investigator_affiliation>
    <investigator_full_name>Giv Heidari-Bateni</investigator_full_name>
    <investigator_title>Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Coenzyme O10</keyword>
  <keyword>Children</keyword>
  <keyword>Idiopathic Dilated Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients younger than 18 years with known diagnosis of primary dilated cardiomyopathy referred for follow-up echocardiography to Children’s Medical Center between September 2006 to March 2008 were recruited.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Coenzyme Q10</title>
          <description>Known cases of idiopathic dilated cardiomyopathy who received Co Q10</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Known cases of idiopathic dilated cardiomyopathy who received the placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conezyme Q10</title>
          <description>known cases of idiopathic dilated cardiomyopathy who received Co Q10</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>known cases of idiopathic dilated cardiomyopathy who received the placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3" spread="4.5"/>
                    <measurement group_id="B2" value="7.3" spread="5.2"/>
                    <measurement group_id="B3" value="6.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Number of patients with evidence of adverse reaction to coenzyme Q10 including nausea, vomiting, changes in blood pressure, neurological signs or any abnormal behavior like disquiet in young children.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conezyme Q10</title>
            <description>Known cases of idiopathic dilated cardiomyopathy who received Co Q10</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Known cases of idiopathic dilated cardiomyopathy who received the placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of patients with evidence of adverse reaction to coenzyme Q10 including nausea, vomiting, changes in blood pressure, neurological signs or any abnormal behavior like disquiet in young children.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Left Ventricular Ejection Fraction</title>
        <description>Ejection Fraction of left ventricle (percentage of blood pumped out of left ventricle with each heart beat) calculated by echocardiography</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conezyme Q10</title>
            <description>Known cases of idiopathic dilated cardiomyopathy who received Co Q10</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Known cases of idiopathic dilated cardiomyopathy who received the placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Left Ventricular Ejection Fraction</title>
          <description>Ejection Fraction of left ventricle (percentage of blood pumped out of left ventricle with each heart beat) calculated by echocardiography</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" spread="14.7"/>
                    <measurement group_id="O2" value="37.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Left Ventricular Filling Abnormality</title>
        <description>Doppler-derived transmitral blood flow and pulmonary venous blood flow data were used for grading of the severity of diastolic filling abnormality in patients before and after the intervention. Diastolic filling abnormality was categorized as: 1- normal 2- abnormal relaxation 3- pseudonormal 4- restricted pattern based on echo data. The proportion of patients who showed improvement in the diastolic function grading was compared between the study groups.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conezyme Q10</title>
            <description>Known cases of idiopathic dilated cardiomyopathy who received Co Q10</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Known cases of idiopathic dilated cardiomyopathy who received the placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Left Ventricular Filling Abnormality</title>
          <description>Doppler-derived transmitral blood flow and pulmonary venous blood flow data were used for grading of the severity of diastolic filling abnormality in patients before and after the intervention. Diastolic filling abnormality was categorized as: 1- normal 2- abnormal relaxation 3- pseudonormal 4- restricted pattern based on echo data. The proportion of patients who showed improvement in the diastolic function grading was compared between the study groups.</description>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Coenzyme Q10 (Study Group)</title>
          <description>Known cases of idiopathic dilated cardiomyopathy
Coenzyme Q10: dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient’s tolerance</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Control Group)</title>
          <description>Known cases of idiopathic dilated cardiomyopathy
Placebo: dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient’s tolerance</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Giv Heidari-Bateni MD/MPH</name_or_title>
      <organization>Children's Medical Center</organization>
      <phone>3142991984</phone>
      <email>givhb@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

